Replies to post #35449 on Humanigen Inc (fka HGENQ)

[cowtown jay]

Thank you for your post, Protector. I really appreciate when people share their thoughts about Humanigen in the way you just did.

I agree with you about the market doing the opposite of what is expected in front of news regarding clinical trial results. And I think, more than ever, that we might slide below $2 (and fill my open buy order at $1.99). That's IF we don't announce some news before the market re-opens on Monday.

I also think, like you, that we could see foreign approval before that from the FDA. But I have hope that we won't see a "sudden drop" after a spike upwards on a foreign approval. To avoid that, we need revenue news, at the same or near the same time.

Not only do I think that is feasible, I expect it, from two different sources. Even without FDA approval, I expect we will get news regarding government stockpile orders. In addition, I think we may see purchases through Clinigen being announced, especially in France, where we will be selling under a 'named cohort' authorization.

In fact, there is a third source of revenue we may receive, even without an EUA. It is not from product sales. It would be from financial assistance from BARDA and CRADA. We have not received support from them financially.

That is unlike the support from the US government agencies that Novavax has received, and which enabled NVAX to report an increase in revenue from $18.7M in 2019, up to $475.6M in 2020.

see page 52 for that detail, but I recommend also reading Items 6 and 7, from pp 52-58.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069421000004/nvax-20201231.htm#i633e70a4a76745feaf5c1ac333a03591_37

"Funding for our NVX-CoV2373 clinical development program encompasses over $2 billion from sources including CEPI, the DoD, and OWS." (p 54)

And as a reminder:

U.S. government to purchase $1B of sotrovimab COVID-19 treatment from GSK, Vir Biotechnology

https://homelandprepnews.com/stories/74836-u-s-government-to-purchase-1b-of-sotrovimab-covid-19-treatment-from-gsk-vir-biotechnology/?amp

Without an EUA from the FDA, I could see a spike in our share price, based on product sales, and then see some retracement of the gain. But I think we'll be on a different playing field. NVAX went to a market cap of $20B, and now they're at $6B or so, which is where I want to see HGEN. And NVAX finally submitted their EUA application to the FDA in the last week or so.

Good luck to us trying to add in the $1 range. I need the help, and I have been more than patient.

[Protector]

With pain in my hart for all HGEN holders, but as I envisaged would happen, sub 2$ touched.

then again, as I suggested in the related post this might be a signal of good news coming in time. Possibly related to some non-US approvals for Lenz (SPECULATION)

AIMO